Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib after reduced-intensity allogeneic transplant for imatinib-resistant or imatinib-intolerant chronic myeloid leukemia
ISRCTN12974558Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by University of Birmingham. Primary endpoint: Safety and tolerability of nilotinib therapy. Started Nov 2008; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN12974558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12974558.